Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Near Market Launch
View:
Post by WarrantOfficer on Jan 13, 2025 9:00am

Near Market Launch

I have heard "paved the road for near market launch" so often over the years that road could run from Anchorage to Ottawa. All joking aside, I was under the impression that testing had begun mid Nov 2024. Remaining, it is forward traction.
Comment by postie1 on Jan 13, 2025 9:13am
I was under that impression also. That being said I am still of my opinion that VM is worth much more right now than what the price is at right now. That top 5 company is not looking to partner up just for the fun of it
Comment by phoenix1151 on Jan 13, 2025 12:58pm
I believe such testing has been completed for 1 product (SmoothX), as there was a white paper issued.  Now it's time to proceed with other products in Q1 and Q2.
Comment by Taz5656 on Jan 13, 2025 1:35pm
Human Trials did start Nov 15th but they were not allowed to release that news during the PP. The plan was to release it before Christmas after the close of the PP but they released the LOI and did not get a good response from that so they decided to wait till Jan.
Comment by WarrantOfficer on Jan 14, 2025 6:50am
Taz5656. I ponder why would they state "commence human testing" which means has begun, if in fact testing began in mid Nov 2024. A statement indicating that testing continues would be more relevant?  
Comment by postie1 on Jan 14, 2025 8:08am
I think that possibly the release was madefora couple of months ago and not updated to reflect current reality. The timeline for length of trial  would probably match what Taz is saying. These guys are obviously not pumpers or there would be better and many more releases. Still long
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1